Filing Flows › Health Care › BioAge Labs (BIOA)
BioAge Labs (BIOA) earnings and revenue breakdown
Latest: Q3 2026 · 10-Q filed Nov 5, 2026 · BioAge Labs (BIOA) Q3 2026 earnings results →
Q3 2026 Revenue down 86% year over year to $298K
BioAge Labs made $298K in Q3 2026 (-86% Y/Y). Operating margin n/m, net loss $33.5M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Nov 5, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $298K in Q3 2026, down 85% year over year and down 88% from the previous quarter.
Operating costs exceeded revenue by $37.4M, an operating margin of -12554.0%. Total costs grew 50% against a revenue fall of 85%. The fastest-growing cost line was Research & development (+63%). The quarter ended with a net loss of $33.5M, wider than the previous quarter's $26.1M loss.
Operating cash flow was −$31.0M. Non-cash charges added back $100K of depreciation and $4.6M of share-based compensation. Working capital and other items used $2.2M. Capital expenditures of $18K exceeded it, leaving free cash flow of −$31.0M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q3 2026 | 10-Q | Nov 5, 2026 | $298K | -86% | n/m | −$33.5M | −$31.0M |
| Q2 2026 | 10-Q | Aug 5, 2026 | $2.5M | +2% | n/m | −$26.1M | −$19.3M |
| Q1 2026 | 10-Q | May 8, 2026 | $2.8M | +91% | -915.4% | −$22.3M | −$24.0M |
| Q4 2025 | 10-K | Mar 24, 2026 | $3.1M | — | -923.4% | −$25.9M | −$28.3M |
| Q3 2025 | 10-Q | Nov 6, 2025 | $2.1M | — | n/m | −$20.2M | −$16.0M |
| Q2 2025 | 10-Q | Aug 6, 2025 | $2.4M | — | n/m | −$21.6M | −$20.0M |
| Q1 2025 | 10-Q | May 6, 2025 | $1.5M | — | n/m | −$12.9M | −$17.4M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About BioAge Labs
We are a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging. Our technology platform and differentiated human datasets enable us to identify promising targets based on insights into molecular changes that drive aging. In January 2025, we announced the nomination of our lead program, BGE-102, a potent, structurally novel, orally available, brain-penetrant small-molecule NLRP3 inhibitor. BGE-102 has a distinct mechanism and binding site from other NLRP3 inhibitors in development with issued patents covering both composition of matter and claims for the unique binding site.
In its own words, from its 10-K, filed Mar 24, 2026.
BioAge Labs against its Pharmaceutical Preparations peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: -86% against the peers' median +7%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| BIOA BioAge Labs | Q3 2026 | $298K | -86% | n/m |
| JNJ Johnson & Johnson | Q3 2026 | $25.4B | +6% | 0.1% |
| LLY ELI Lilly | Q3 2026 | $24.4B | +39% | 34.5% |
| MRK Merck | Q3 2026 | $18.1B | +5% | 30.7% |
| ABBV AbbVie | Q3 2026 | $17.4B | +10% | 36.0% |
| PFE Pfizer | Q3 2026 | $16.6B | -0.4% | 20.4% |
| BMY Bristol Myers Squibb | Q3 2026 | $13.1B | +7% | 19.4% |
| ABT Abbott Laboratories | Q3 2026 | $13.0B | +14% | 10.4% |
| REGN Regeneron Pharmaceuticals | Q3 2026 | $5.1B | +36% | 40.0% |
Source: BioAge Labs 10-Q on SEC EDGAR · CIK 1709941 · Pharmaceutical Preparations
13F: who owns BIOA and who is buying
More on BIOA
History
Every quarter: Q3 2026 results · Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results